The short version of WADA Prohibited List fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-01. Anything still debated is marked as such rather than presented as settled.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
For example, in the chemical structure of canagliflozin, a fluorine atom is connected to an aromatic ring, making the compound more stable and reducing the metabolism of the compound. Empagliflozin contains a tetrahydrofuran ring but not canagliflozin nor dapagliflozin.
Because of the double-stranded nature of DNA, essentially all of the nucleotides take the form of Watson–Crick base pairs between nucleotides on the two complementary strands of the double helix. In contrast, both RNA and proteins are normally single-stranded. Therefore, they are not constrained by the regular geometry of the DNA double helix, and so fold into complex three-dimensional shapes dependent on their sequence. These different shapes are responsible for many of the common properties of RNA and proteins, including the formation of specific binding pockets, and the ability to catalyse biochemical reactions.
The vagrant population of the Bowery declined after the 1970s, in part because of the city's effort to disperse it. Since the 1990s the entire Lower East Side has been reviving, and gentrification has contributed to ongoing change along the Bowery. In particular, the number of high-rise condominiums is growing. In 2007, the SANAA-designed facility for the New Museum of Contemporary Art opened between Stanton and Prince Street. In 2008, AvalonBay Communities opened Avalon Bowery Place, its first luxury apartment complex on the Bowery; the structure includes a Whole Foods Market. Avalon Bowery Place was quickly followed with the development of Avalon Bowery Place II. The new development has not come without social costs. Michael Dominic's 2001 documentary Sunshine Hotel followed the lives of residents of one of the few remaining flophouses. Construction on the Wyndham Garden Hotel at 93 Bowery in the late Aughts destabilized neighboring building 128 Hester Street (owned by the same man, William Su), and 60 tenants were thrown out of the building with the help of the Department of Buildings. At least 75 tenants were displaced from 83 to 85 Bowery in January 2018 in frigid temperatures due to long-overdue repairs that needed to be made. Tenants accused the landlord of using this displacement to start renovating the buildings into a hotel, and they went on a hunger strike. The Bowery from Houston to Delancey Street still serves as New York's principal market for restaurant equipment and from Delancey to Grand for lamps.
Sources: en.wikipedia.org
Crystallization of ubiquitin protein was successfully done using racemic crystallography. Crystallization of either D-ubiquitin or L-ubiquitin alone is difficult, whereas a racemic mixture of D-ubiquitin and L-ubiquitin was readily crystallized and diffraction quality crystals were obtained overnight in almost half the conditions tested in a standard commercial crystallization screen. Crystallization of racemates of disulfide-containing microprotein molecules was used to determine the structure of trypsin inhibitor SFTI-1 (14 amino acids,1 disulfide), conotoxin cVc1.1 (22 amino acids, 2 disul-fides) and cyclotide kB1 (29 amino acids, 3 disulfides). Using X-ray diffraction, it was found that the racemates crystallized in the centrosymmetric spacegroups P3(bar), Pbca and P1(bar). Interestingly, achiral "'peptoid'" chains were found to fold as racemic pairs and crystallize in highly preferred centrosymmetric space groups. A high-resolution crystal structure of the racemate of a heterochiral D-protein complex with vascular endothelial growth factor A (VEGF-A). The mirror image D-protein form of VEGF-A was used in phage display to identify a 56 residue L-protein binder with nanomolar affinity; the chemically synthesized D-protein binder had the same affinity for the L-protein form of VEGF-A. A mixture of chemically synthesized proteins consisting of D-VEGF-A, L-VEGF-A, and two equivalents each of the D-protein binder and L-protein binder, gave racemic crystals in the centrosymmetric space group P21/n.
Xanthophylls (originally phylloxanthins) are yellow pigments that occur widely in nature and form one of two major divisions of the carotenoid group; the other division is formed by the carotenes. The name is from Greek: xanthos (ξανθός), meaning "yellow", and phyllon (φύλλον), meaning "leaf"), due to their formation of the yellow band seen in early chromatography of leaf pigments.
Monks whose bodies remain incorrupt without any traces of deliberate mummification are venerated by some Buddhists who believe they successfully were able to mortify their flesh to death. Self-mummification was practiced until the late 1800s in Japan and has been outlawed since the early 1900s. Many Mahayana Buddhist monks were reported to know their time of death and left their last testaments and their students accordingly buried them sitting in lotus position, put into a vessel with drying agents (such as wood, paper, or lime) and surrounded by bricks, to be exhumed later, usually after three years. The preserved bodies would then be decorated with paint and adorned with gold. Bodies purported to be those of self-mummified monks are exhibited in several Japanese shrines, and it has been claimed that the monks, prior to their death, stuck to a sparse diet made up of salt, nuts, seeds, roots, pine bark, and urushi tea.
== Pathophysiology == The cause of the disease is the lack of a fully functional insulin receptor, which has a profound effect during fetal development and thereafter. In one case, it was found (by culturing pancreatic cells) that the receptor produced by the mutant allele is only about 15% as effective as the normal receptor. The beta cells in the pancreas, which make and store insulin and release it on an as-needed basis, are often found to be very large or numerous. The role of insulin in the body is to facilitate the entrance of glucose into the cell. Once insulin binds to the insulin receptors on the cell surface, the insulin receptors will send a signal that will ultimately bring the glucose transporter protein GLUT4 to attach to the cell membrane. Additionally, once insulin is bound to the insulin receptors, it will also initiate several signaling cascades that will promote cell growth and differentiation, protein synthesis, glucose synthesis, and the inhibition of gluconeogenesis through several metabolic pathways. A malfunctioning insulin receptor would thus not be able to properly initiate the signaling cascades for the aforementioned cellular processes. Many of the problems associated with Donohue syndrome may be due to the insulin receptor binding the insulin-like growth factor, regulating the growth of the embryo, in addition to its well-known role in the regulation of blood sugar.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.